Nigeria has expanded its malaria vaccination programme to additional states as part of a renewed effort to curb the country’s high malaria burden. The expansion was announced by Dr. Muyi Aina, Executive Director of the National Primary Health Care Development Agency, during the agency’s first quarterly media conference for 2026 in Abuja. Initially piloted in Bayelsa and Kebbi states, the programme has now been extended to Bauchi and Ondo following readiness assessments.
Funding for the programme comes from both federal allocations and development partners, particularly Gavi, the Vaccine Alliance. However, Dr. Aina warned that external support is diminishing and that countries are expected to increase domestic financing. “Vaccine financing covers procurement, outbreak response, as well as logistics including syringes, waste‑management systems, incinerators, and cold‑chain equipment,” he said, noting that operational costs for nationwide immunisation delivery represent a significant portion of government investment.
The malaria vaccine presents a unique challenge because it requires a four‑dose schedule, making consistent follow‑up essential for full protection. “What is unique about the malaria vaccine is that it requires four doses, and ensuring children return for all doses remains a key challenge,” Aina explained. Dropouts between doses have emerged as a major concern, prompting the government to strengthen tracking and follow‑up systems across states.
According to Aina, vaccine administration has steadily increased across implementing states. “In the area of coverage, a total of 984,559 children have received at least one dose in Kebbi and Bayelsa, while Ondo recorded more than 166,342 children and Bauchi 105,890. This brings the total number of children reached to almost 1.3 million,” he said. He also disclosed that more than 600,000 vaccine doses are currently stored in the national cold‑chain system for ongoing and future distribution.
Dr. Aina described vaccines as one of the most effective and cost‑efficient public‑health interventions, emphasizing their safety profile. “Vaccines are much safer and much cheaper than most medicines people buy in stores or use for malaria treatment,” he noted, adding that vaccines undergo strict testing and regulatory evaluation before approval. “Vaccines are highly effective in preventing diseases such as measles. Their success often leads to reduced visibility of such diseases in communities,” he emphasized. While acknowledging that all medical interventions may have side effects, he affirmed that vaccines remain among the most thoroughly tested and safest preventive tools.
He called for sustained public confidence in immunisation programmes and health workers, noting that the government is investing in incentives and staffing to strengthen vaccine delivery. He also observed that immunisation efforts are often underappreciated despite heavy government investment, reiterating that vaccination programmes frequently go unnoticed.
Nigeria’s expansion of malaria vaccination into additional states marks a significant milestone in its public‑health response to one of the country’s most persistent killers. Officials say sustaining progress will depend on improved domestic financing, stronger logistics systems, and ensuring children complete the full four‑dose schedule needed for effective protection. As donor funding tightens and demand rises, the durability of Nigeria’s malaria vaccine rollout will increasingly rely on how quickly domestic systems can shoulder the growing immunisation agenda.
Comments are closed for this story.